THERAPEUTIC ANTISENSE AGENTS AND APTAMERS - PowerPoint Presentation

Slide1

THERAPEUTIC ANTISENSE AGENTS AND APTAMERS

By

NARENDAR.D

M.PHARM.

II - SEMESTER

Department of Pharmaceutics

University College of Pharmaceutical Sciences,

KAKATIYA UNIVERSITY

Warangal - 506009

Slide2

CONTENT

INTRODUCTION

ANTISENSE AGENTS

DEFINITION

MECHANISM

ADVANTAGES

CELLULAR ACTIVITY

CELLULAR UPTAKE

CLINICAL TRIAL SUBSTANCES

APTAMERS

DEVELOPMENT

PROPERTIES

ADVANTAGES AND DISADVANTAGES

APPLICATIONS

CONCLUSION

REFERENCES

Slide3

INTRODUCTION

The term ‘Antisense Therapeutics’ or ‘Antisense Technology’ encompasses several types of nucleic acids that have the ability to modulate gene expression. The most common types of nucleic acids included in this term are antisense oligonucleotides (ODNs), ribozymes (RNA enzymes) and more recently, DNAzymes (DNA enzymes).

Slide4

Antisense refers to the use of short, Single stranded synthetic ONs to inhibit gene expression.

These compounds are designed to be complementary to the coding (sense) sequence of RNA inside the cell.

After hybridization to

target sequences, translational arrest occurs via

one of several putative mechanisms

.

Definition:

Slide5

OLIGONUCLEOTIDE

Also called oligos.

Sequence of DNA or RNA with a phosphate

backbone but may have a sulfate, peptide, or

morpholino backbone in place of phosphate

one, to reduce or eliminate oligo degradation

nucleases.

Main backbone of ONs is the phospodiaste.

Slide6

MECHANISM

First is the ribosomal blockade where the antisense molecule hybridizes to the sense sequence and prevents the ribosome from reading the mRNA code, resulting in production of a defective nonfunctional protein.

The second is the specific cleavage of RNA strand by activated RNAaseH following RNA-ON hybridization. This cleavage results in destruction of the coding message and inhibition of protein synthesis.

The third is the competition between the ribosome and the antisense ON for binding to the 5’untranslated region (.5’-UTR) of the mRNA.

Slide7

Binding of the ON to the 5’-UTR can also result in activation of RNase H and subsequent cleavage of the mRNA. Finally, synthesis of fully mature mRNA in the cytosol can also be prevented at the level of RNA transcription, splicing, processing. Or transport across the nuclear membrane.

For example, ON can bind to the complementary sequence on nuclear DNA. forming triplex DNA which selectively inhibits DNA transcription.

Slide8

ADVANTAGES:

Mature technology (20 years in development).

Drug discovery and research is faster and more predictable.

Compounds are potentially more selective, effective and less toxic.

Broad disease application.

Dosing advantages (route and frequency).

Specificity and is the relative simplicity in which the drugs can be rationally designed.

Slide9

Antisense activity at barriers

First, the ONs must find their way to target cells where they must then penetrate the plasma membrane to reach their target site in the cytoplasm or nucleus.

Second, once inside the cell the ON must be

able to withstand enzymatic degradation

presented by various endogenous nucleases.

Third, the ON must be able to find and then bind

specifically to its intended target site in order to

inhibit expression of the disease-causing gene.

Slide10

Stability and chemical modification

The initial successful demonstrations of the antisense strategy in cell culture employed the naturally occurring phosphodiester ONs.

Phosphodiester ONs are easily degraded in cell culture medium containing serum due to 3’-exonuclease digestion. Consequently, the antisense effects could only be observed if high ON concentrations

(up to 100 PM) were used.

Protection from degradation can be achieved by the use of a “3’-end cap” strategy in which nuclease-resistant linkages are substituted for phosphodiester linkages at the 3’ end of the ON . Alternatively, ONs containing a 3’-terminal hairpin-like structure were found to exhibit improved resistance to exonuclease digestion.

Slide11

Phosphodiester ONs enter cells, they can be further degraded by cellular endonucleases. Neither 3’-end caps nor 5’-end caps protect ONs from degradation in HeLa cell extracts.

Thus, phosphodiester ONs are poor candidates for use as therapeutic agents in vivo. Consequently a number of chemical modifications have been made to improve enzymatic stability of these compounds while preserving their ability to hybridize to cognate targets. The most commonly used are the first-generation analogs that possess modifications of the phosphodiester backbone.

Examples of these include the phosphorothioate and phosphorodithioate analogs which have sulfur

substituted for one or both nonbridging oxygens.

Slide12

Cellular uptake of aptamers

Cellular uptake of ONs is an energy-dependent process and can be inhibited by treating the cells with metabolic inhibitors or by lowering the temperature.

This transport across the membrane takes place in a saturable and sequence-independent manner. Any sequence or size of ribo- and deoxyribonucleotide was demonstrated to compete with labeled ON for uptake. The uptake is endocytic and appears to be mediated by membrane receptor proteins.

Several approaches have been developed to improve cellular uptake of ONs. These include inclusion of ONs into liposomes or attaching them covalently or electrostatically to specific or nonspecific carriers.

Slide13

Liposome-mediated antisense delivery Cationic liposomes which can form stable complexes with the polyanionic ONs. These liposomes consist mainly of a positively charged lipid, most notably N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride or DOTMA, and a co-lipid.

E.g. dioleylphosphatidylethanolamine, to aid cytoplasmic delivery of the polynucleotides.

Recently, several different types of cationic lipids have been developed including lipofectin, quaternary ammonium compounds, cationic derivatives of cholesterol- diacyl glycerol and lipid derivative of polyamines

Slide14

Carrier system

Mechanism

Liposomes

Cationic Adsorptive endocytosis

pH-sensitive Non-specific endocytosis/ Endosomal

membrane fusion

Immunoliposomes Receptor-mediated endocytosis

Sendai virus-derived liposomes Plasma membrane fusion

`

Poly(L-lysine)

Adsorptive endocytosis

Avidin

Adsorptive endocytosis

Acridine

Intercalation

Slide15

Polylysine- mediated antisense delivery

Poly( r_-lysine (PLL), a well-known polycationic drug carrier, has been used to facilitate cellular uptake of various drugs including antisense ONs. Using VSV-infected L929 cells as a model system, Lemaitre and Leonetti et al. demonstrated that ONs complementary

to viral nucleocapsid initiation site or to viral genomic RNA sequences promoted a sequence-specific and dose-dependent antiviral activity when administered as PLL conjugates.

Antiviral activities of such conjugates were observed

at concentrations below 1 PM while nonconjugated ONs were equally active when used at concentrations greater than 50 ,uM. Likewise, PLL-conjugated ONs complementary to a HIV-1 splice site inhibited cytopathic effects at much lower concentrations than non-conjugated phosphodiester or methylphosphonate ONs.

Slide16

Other methods of antisense delivery

ON modifications reported to increase cellular uptake include the attachment of hydrophobic molecules, such as cholesterol and phospholipids, to the ONs.

Coupling of a single cholesterol moiety to an ON appears to increase its intracellular uptake by up to 1%fold.

Similarly, anti-HIV cholesteryl-conjugated ONs are more effective than their unmodified counterparts.

Similarly, conjugation of an ON to phospholipids was shown to promote its anti-tumor activity. It is not known from these studies whether endocytosis is involved in the uptake of modified ONs

.

Avidin, a cationic protein known to internalized via an adsorptive endocytosis process, has been coupled to ONs Association of a biotin-conjugated ON with avidin is rapid and of high affinity. Cellular uptake of an avidin-biotin- ON complex was shown to be 4-fold more efficient than the biotin-ON conjugate alone

.

Slide17

Example clinical trials studies involving antisense oligonucleotides--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ODN Target Therapeutic Class Clinical Trial hase Company

-----------------------------------------------------------------------------------------------------------------------------------------------------------

Vitravene CMV Retinitis Anti-viral in Approved Isis AIDS patients CIBAVision

ISIS 2302 ICAM-1 Renal transplant rejection Phase II Isis

Psoriasis (topical) Phase IIa

Ulcerative colitis (enema) Phase IIa

ISIS 3521 PKC-alpha Cancer Phase II Isis

ISIS 5132 c-raf kinase Cancer Phase II Isis

ISIS 2503 Ha-ras Cancer Phase II Isis

ISIS 14803 HCV Hepatitis C Phase I / II Isis /Elan

GEM231 Protein kinase A 1a Cancer Phase II Hybridon/methylgene

MG98 DNA methyltransferas Cancer Phase 1 Hybridon/ methylgene

Slide18

APTAMERS

Aptamers are artificial nucleic acid ligands that can be generated against amino acids, drugs, proteins and other molecules. They are isolated from complex libraries of synthetic nucleic acid by an iterative process of adsorption, recovery and reamplification. They have potential applications in analytical devices, including biosensors, and as therapeutic agents.

Also defined as aptamers are oligonucleotide sequence that bind ligands or antigens in a way that is similar in may respects to antibody-ligand interactions.

Slide19

Aptamers range in size from approximately 6 to 40 k Da and sometimes have complex three-dimensional structures, produced by a combination of Watson–Crick and non-canonical intramolecular interactions.

More specifically, aptamers can be classified as:

DNA

or

RNA

aptamers. They consist of (usually short) strands of oligonucleotides.

Peptide

aptamers. They consist of a short variable peptide domain, attached at both ends to a protein scaffold.

Slide20

DEVELOPMENT OF APTAMERS

Isolation of nucleic acids from artificial libraries on the basis of their biochemical properties were being widely discussed during 1988 and 1989, three groups independently published their results in 1990.

First, the Joyce group reported the use of

in vitro

mutation, selection and amplification to isolate RNAs that were able to cleave DNA.

Second, the Gold group described experiments designed to identify the sequence requirements of T4 DNA polymerase.

‘SELEX’ (selective expansion of ligands by exponential enrichment), was able to identify the natural target of the enzyme as the predominant, high-affinity ligand, with one major variant emerging with similar affinity.

Slide21

PROPERTIES OF APTAMERS

Structures Aptamer Size

Aptamer Targets

Affinity

Slide22

Structure:

Determined by - enzymatic probing - chemical probing - NMR - X-ray crystallography

NMR has disadvantages

- small size and rigidity when complexed with target.

- similariries between the interaction sites between protien ligands and their receptrors.

Slide23

Aptamer size:

Size of aptamer depends on sequence family.Minimum within VEGF aptamers was between 23 and 35 nt ; minimum xanthine and guanine aptamers were 32 nt long.Solvent-exposed surface area for a typical aptamer expected to be in the range 50-60 nm2.

Slide24

Aptamer targets:

Aptamers targeted against small ions, such as zinc, to nucleotides such as ATP, oligopeptides and large glycoproteins such as CD4, size range 65kDa-150kDa, with no theoretical upper limit.

Slide25

Aptamer affinity:

Aptamers against small molecules have affinities in micromolar range. against aminoacids such as citrulline and arginine range from 0.3 to 65µM, and those against ATP and xanthine are 6 and 3.3

µ

M respectively.

Aptamers to nucleic acid-binding molecules have affinities in the nanomolar range.

against retroviral integrase – 10-800nM

reverse transcriptase – 0.3-20nM

Slide26

ADVANTAGES

Used To analyze the natural processes of nucleic acid–protein recognition.

To generate inhibitors of enzymes, hormones and toxins with potentially pharmacological uses.

To Detect the presence of target molecules in complex mixtures and to generate lead compounds for medicinal chemistry.

Their advantages over alternative approaches include the relatively simple techniques and apparatus required for their isolation, the number of alternative molecules that can be screened (routinely of the order of 1015) and their chemical simplicity.

Slide27

Disadvantages

of aptamers include:

their pleiomorphism,

their high molecular mass,

the restricted range of target sites that appear to be suitable.

Slide28

IN VIVO APPLICATION OF APTAMERS

 

Aptamers targeting coagulation factors

     

E.g against factor IXa

Aptamers targeting growth factors or hormones

      E.g against VEGF

Aptamers targeting antibodies involved in autoimmune diseases

     

E.g. auto-antibodies against nicotinic AChRs (for m gravis)

Slide29

Aptamers targeting inflammation markers

    

E.g against elastase

Aptamers targeting neuropathological targets

 

E.g against synthetic βA amyloid peptide (Alzheimer)

Aptamers against infectious diseases

     

E.g against gp120 or HA

Aptamers targeting membrane biomarkers

     

E.g against CTL-4

Aptamers targeting whole organisms

      

E.g against CMV

 

 

 

 

 

Slide30

Slide31

Conclusion

Slide32

Conclusion

Slide33

REFERENCES

Y. Rojanasakul - Advanced Drug Delivery Reviews 18 (1996) 115-131

S. Akhtar et al - Advanced Drug Delivery Reviews 44 (2000) 3 –21

R.J. Boado - Advanced Drug Delivery Reviews 15 (1Wf) 7% 107

James swarbrick – Encyclopedia of pharmaceutical technology 3- edition, volume-2 935-936

James swarbrick – Encyclopedia of pharmaceutical technology 3- edition, volume-3 1575-1576

Slide34

William James; Encyclopedia of Analytical Chemistry;

pp. 4848–4871S.P.Vyas and Roop K. Khar; targeted & Controlled drug delivery: Novel Carrier Systems,

www.pharmainfo.net.com

www.wikipedia.org

www.informaworld.com

Slide35

Conclusion

Slide36